No Data
Eagle Eye Technology (02251.HK): The gradual release of growth elasticity, looking at AI diagnosis and treatment integrated commercial application models.
In recent years, AI technology has triggered an unprecedented revolution in the medical field, from assisting in diagnosis to empowering medical imaging, and even to drug development. The power of AI is gradually permeating and reshaping every corner of the medical industry. In this context, how can investors seize the deterministic opportunities in the AI medical field? Which companies can stand out and become the backbone of the industry? In the eyes of industry observers, AI medical companies that are the first to explore commercial landing paths and have self-regenerating capabilities are more investment-worthy. These companies generally have strong research and development capabilities and market insights, allowing them to stand firm in intense market competition.
Express News | Airdoc Technology 2024 Interim Results: Solid Growth in Revenue and Gross Profit
Eagle Eye Technology - B (02251): Wu Gangping resigns as an independent executive director.
Eagle Eye Technology -B (02251) announced that on the date of this announcement, Wu Gangping has resigned as an independent executive director in order to devote himself to...
Eagle Eye Technology-B (02251): It is recommended to adopt the stock-based incentive plan for 2024.
Eagle Vision Technology -B(02251) announced in a statement that on August 28, 2024, the board of directors decided to hold an extraordinary shareholder meeting...
Eagle Eye Technology-B (02251) plans to submit the full circulation of H-shares in 2024 to shareholders at the extraordinary general meeting.
Eagle Eye Technology-B (02251) announced that at the meeting held on August 28, 2024, the board of directors approved...
Yingtong Technology (02251) 2024 midterm performance: steady growth in revenue and gross profit, further consolidating its leading position in the industry.
On August 28th, Eagle Eye Technology (02251) released its performance report for the first half of 2024. In the first half of 2024, ...
No Data
